Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Few Thoughts and a Look at the Earnings in the Coming Week
Jul 28, 2008 01:20 AM
- NASDAQ Technical Picture - Expansion
May 02, 2008 02:01 AM
- NASDAQ Technical Picture - Lowest Close Since Oct. 2006
Mar 07, 2008 10:05 AM
- NASDAQ Technical Picture - Lowest Close Since Oct. 2006
Mar 02, 2008 11:11 PM
- Buffett To The Rescue
Feb 12, 2008 09:43 AM
- Retail Sales, Inflation, & Citigroup
Jan 15, 2008 10:09 AM
- January Barometer
Jan 02, 2008 10:23 AM
- Mixed News & Poor Sentiment
Dec 13, 2007 10:23 AM
- DepoMed, King Pharma End Pact On Type 2 Diabetes Drug
Oct 29, 2007 04:46 PM
- DepoMed, King Pharma End Pact On Type 2 Diabetes Drug
Oct 29, 2007 04:46 PM
- Covidien and Depomed Announce License Agreement
Nov 24, 2008 08:41 AM
- Depomed, Inc. Announces Conference Call to Discuss Exclusive North American License Agreement with Solvay Pharmaceuticals, Inc.
Nov 21, 2008 04:21 PM
- Depomed, Inc. Announces Exclusive North American License Agreement with Solvay Pharmaceuticals, Inc. for DM-1796 (Gabapentin GR®) in the Treatment of Pain
Nov 20, 2008 04:05 PM
- Solvay Pharmaceuticals, Inc. Announces Exclusive North American License Agreement with Depomed, Inc. for Gabapentin GR® for the Treatment of Neuropathic Pain
Nov 20, 2008 04:03 PM
- Depomed Reports Third Quarter 2008 Financial Results
Oct 30, 2008 04:19 PM
- Depomed To Present at Three Upcoming Conferences
Oct 24, 2008 06:31 AM
- Depomed Initiates Second Phase 3 Trial in Menopausal Hot Flashes
Oct 20, 2008 06:33 AM
- Depomed to Announce Third Quarter 2008 Financial Results on October 30, 2008
Oct 16, 2008 06:31 AM
- Depomed Announces Presentation of Clinical Data at the North American Menopause Society Annual Meeting
Sep 25, 2008 04:07 PM
- Depomed to Present at the UBS Global Life Sciences Conference
Sep 18, 2008 02:40 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
DEPO
|
Compare to S&P
|
| YTD |
-52.45 %
|
-22.10 %
|
| 4 Weeks |
-28.24 %
|
-22.43 %
|
| 12 Weeks |
-63.53 %
|
-49.45 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -300.00 %
|
|
EPS Growth in Last Year: 40.00 %
|
|
Sales Growth in Last Quarter: 123.45 %
|
|
Sales Growth in Last Quarter: -73.30 %
|
|
|
